Evidence map›Paper›PMID 37344864›Full record

ArticleJournal of orthopaedic surgery and research2023

MiR-137 promotes TLR4/NF-κB pathway activity through targeting KDM4A, inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis.

Ying-Feng Yu, Pei-Quan Yao, Zhi-Kun Wang, Wen-Wei Xie

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ying-Feng YuDepartment of Orthopedics, Songshan Lake Central Hospital of Dongguan City, Dongguan, Guangdong, China.
Pei-Quan YaoDepartment of Orthopedics, Songshan Lake Central Hospital of Dongguan City, Dongguan, Guangdong, China.
Zhi-Kun WangDepartment of Orthopedics, Songshan Lake Central Hospital of Dongguan City, Dongguan, Guangdong, China.
Wen-Wei XieDepartment of Orthopedics, Songshan Lake Central Hospital of Dongguan City, Dongguan, Guangdong, China. lyd528900@126.com.
Songshan Lake Materials Laboratory · CN

Funding

Dongguan Municipal Bureau of Science and Technology, the key project of Dongguan's social development in 2021 Project No. 20211800904552
6 · The paper itself

Abstract

purposeAs the global population ages rapidly, osteoporotic fractures have become an important public health problem. Previous studies have suggested that miR-137 is involved in the regulation of bone formation, but its specific regulatory mechanism remains unclear. In this study, we aimed to explore the expression, role, and regulatory mechanism of miR-137 in the osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs).

methodshBMSCs were induced into osteoblasts at first, and the expression level of miR-137 at different time points was detected. After knockdown and overexpression of miR-137, the effect of miR-137 on the osteogenic differentiation of hBMSCs was examined through alkaline phosphatase (ALP) staining and Alizarin Red staining. Western blotting was performed to detect the expression of runt-related transcription factor 2 (Runx2), osteocalcin (OCN), and toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) pathway. Bioinformatics websites were used to predict the target binding sites for miR-137 and KDM4A, and the results were validated using luciferase reporter gene experiments. Moreover, the ALP activity, calcium nodule formation, and activation of Runx2, OCN, and TLR4/NF-κB pathways were observed after knockdown of KDM4A.

resultsThe expression of miR-137 decreased during osteogenic differentiation. Knockdown of miR-137 expression increased the osteogenic ability of hBMSCs, while overexpression of it weakened the ability. Through the activation of the TLR4/NF-κB pathway, miR-137 inhibited osteogenic differentiation. KDM4A was identified as a predicted target gene of miR-137. After knocking down KDM4A expression, the osteogenic ability of hBMSCs was diminished, and the TLR4/NF-κB pathway was activated. Furthermore, the osteogenic ability of hBMSCs was partially restored and the activation level of TLR4/NF-κB was reduced after miR-137 knockdown.

conclusionMiR-137 enhances the activity of the TLR4/NF-κB pathway by targeting KDM4A, thereby inhibiting the osteogenic differentiation of hBMSCs and exacerbating osteoporosis.

Indexed as

Mesenchymal Stem CellsMicroRNAsOsteoporosisBone Marrow CellsCell DifferentiationCells, CulturedCore Binding Factor Alpha 1 SubunitHumansJumonji Domain-Containing Histone DemethylasesNF-kappa BOsteogenesisToll-Like Receptor 4Core Binding Factor Alpha 1 SubunitJumonji Domain-Containing Histone DemethylasesKDM4A protein, humanMicroRNAsMIRN137 microRNA, humanNF-kappa BTLR4 protein, humanToll-Like Receptor 4Human bone marrow mesenchymal stem cells (hBMSCs)KDM4AmiR-137OsteoporosisTLR4/NF-κB

Identifiers

PMID37344864
PMCPMC10286393
OpenAlexW4381549475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.